Annual Summary of Stock Exchange Releases published in 2012

21 januari 2013 ORION CORPORATION        STOCK EXCHANGE RELEASE 21 JAN 2013 AT 10:00 a.m. EET In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases published by the company in 2012. The releases are available on the internet website of Orion Corporation, at http://www.orion.fi/se-releases. Orion points out that part of the information in the releases can have become out-dated. Stock Exchange Releases in 2012 +-----------+------------------------------------------------------------------+ |January |  | +-----------+------------------------------------------------------------------+ |20 Jan 2012|Orion invites analysts and media to Financial Statement Release | | |conference on Tuesday 7 February 2012 | +-----------+------------------------------------------------------------------+ |20 Jan 2012|Orion Corporation: Annual Summary of Stock Exchange Releases | | |published in 2011 | +-----------+------------------------------------------------------------------+ |30 Jan 2012|Recommendation by the Nomination Committee concerning Board of | | |Directors to be elected by the 2012 AGM of Orion Corporation | +-----------+------------------------------------------------------------------+ |February |  | +-----------+------------------------------------------------------------------+ |7 Feb 2012 |Orion continues development of inhalable budesonide-formoterol | | |combined formulation | +-----------+------------------------------------------------------------------+ |7 Feb 2012 |Orion Group Financial Statement Release for 2011 | +-----------+------------------------------------------------------------------+ |7 Feb 2012 |Notice to the Annual General Meeting of Orion Corporation | +-----------+------------------------------------------------------------------+ |March |  | +-----------+------------------------------------------------------------------+ |6 Mar 2012 |Orion Group Annual Report 2011 published | +-----------+------------------------------------------------------------------+ |12 Mar 2012|Orion Corporation: Transfer of 87,763 own B-shares on 12 March | | |2012 | +-----------+------------------------------------------------------------------+ |20 Mar 2012|Orion Oyj : Decisions by the AGM on 20 March 2012 | +-----------+------------------------------------------------------------------+ |20 Mar 2012|Orion Oyj : Orion Corporation: Organising meeting of the Board of | | |Directors | +-----------+------------------------------------------------------------------+ |26 Mar 2012|Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a | | |generic version of Orion's proprietary drug Stalevo® in the United| | |States | +-----------+------------------------------------------------------------------+ |April |  | +-----------+------------------------------------------------------------------+ |10 Apr 2012|Orion Corporation: 300,000 Orion A-shares converted into B-shares | +-----------+------------------------------------------------------------------+ |10 Apr 2012|Orion invites analysts and media to Q1 news conference on Tuesday | | |24 April 2012 | +-----------+------------------------------------------------------------------+ |24 Apr 2012|Orion Group Interim Report January-March 2012 | +-----------+------------------------------------------------------------------+ |26 Apr 2012|Orion sues Mylan in the U.S. to enforce its U.S. patents covering | | |the proprietary drug Stalevo® | +-----------+------------------------------------------------------------------+ |May |  | +-----------+------------------------------------------------------------------+ |1 May 2012 |U.S. District Court gives decision on Precedex® patent litigation | +-----------+------------------------------------------------------------------+ |June |  | +-----------+------------------------------------------------------------------+ |July |  | +-----------+------------------------------------------------------------------+ |3 Jul 2012 |Orion upgrades full-year outlook for 2012 | +-----------+------------------------------------------------------------------+ |5 Jul 2012 |200,000 Orion A-shares converted into B-shares | +-----------+------------------------------------------------------------------+ |16 Jul 2012|Orion invites analysts and media to Q2 news conference on Tuesday | | |31 July 2012 | +-----------+------------------------------------------------------------------+ |31 Jul 2012|Orion Corporation's publication schedules for financial reporting | | |in 2013 | +-----------+------------------------------------------------------------------+ |31 Jul 2012|Orion Group Interim Report January-June 2012 | +-----------+------------------------------------------------------------------+ |August |  | +-----------+------------------------------------------------------------------+ |September |  | +-----------+------------------------------------------------------------------+ |5 Sep 2012 |Disclosure Under Chapter 2 Section 10 | +-----------+------------------------------------------------------------------+ |5 Sep 2012 |Orion Corporation: Correction to the English version of the stock | | |exchange release | +-----------+------------------------------------------------------------------+ |12 Sep 2012|200,000 Orion A-shares converted into B-shares | +-----------+------------------------------------------------------------------+ |October |  | +-----------+------------------------------------------------------------------+ |9 Oct 2012 |Orion invites analysts and media to Q3 news conference on Tuesday | | |23 October 2012 | +-----------+------------------------------------------------------------------+ |9 Oct 2012 |Orion upgrades full-year outlook for 2012 | +-----------+------------------------------------------------------------------+ |23 Oct 2012|Orion Group Interim Report January-September 2012 | +-----------+------------------------------------------------------------------+ |23 Oct 2012|Composition of the Nomination Committee of Orion Corporation | +-----------+------------------------------------------------------------------+ |November |  | +-----------+------------------------------------------------------------------+ |19 Nov 2012|823,000 Orion A-shares converted into B-shares | +-----------+------------------------------------------------------------------+ |30 Nov 2012|Orion is planning to apply for a marketing authorisation for | | |combined budesonide-formoterol formulation of the Easyhaler® | | |product family | +-----------+------------------------------------------------------------------+ |December |  | +-----------+------------------------------------------------------------------+ |20 Dec 2012|203,000 Orion A-shares converted into B-shares | +-----------+------------------------------------------------------------------+ |20 Dec 2012|Orion and Mylan settle patent dispute over the proprietary drug | | |Comtan® | +-----------+------------------------------------------------------------------+ Orion Corporation Timo Lappalainen Olli Huotari President and CEO SVP, Corporate Functions Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki. This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Orion Oyj via Thomson Reuters ONE [HUG#1671690]